This site is intended for Great Britain healthcare professionals only 

Visit Pfizer Medical site
Search

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsLet’s ConnectStock Hub

Menu

Close

AboutAboutHow Cibinqo worksIntroducing CibinqoMOA OverviewPatient ProfilesPatient Profiles OverviewPatient Profile 1Patient Profile 2Patient Profile 3Patient Profile 4EfficacyEfficacyClinical EfficacyStudy OverviewJADE COMPAREJADE MONOJADE REGIMENJADE TEENJADE EXTENDSafety
Safety
 
Safety
 
Safety Guidance
DosingDosingDosingOral once-daily dosingPractical ConsiderationsSupport & ResourcesSupport & ResourcesHCP ResourcesMedicine Evidence InformationPatient ResourcesVideos
Materials

Information on how to access Cibinqo® (abrocitinib) prescribing information and adverse event reporting can be found at the bottom of the page.

JADE EXTENDSafety and efficacy of Cibinqo evaluated in an ongoing long term extension study​​​​​​​

​​​​​​​A long-term extension study evaluating the safety and efficacy of Cibinqo, with or without medicated topical therapy, in adults and adolescent patients with moderate-to-severe AD.1,2

STUDY DESIGN1,2

Patients who completed Week 92 and remained eligible could enroll in an open-label treatment period with variable length.

*For patients in JADE REGIMEN, patients must have completed the full open-label run-in period of JADE REGIMEN and failed to meet the protocol-defined response criteria at Week 12.
Patients could continue to receive Cibinqo in the long-term extension trial until availability of commercial Cibinqo or until the study was terminated in their respective country.

Primary endpoints:
  • Incidence of TEAE (treatment-emergent adverse events)
  • Incidence of SAE (serious adverse events) and AEs leading to discontinuation
  • Incidence of clinical abnormalities and change from baseline in clinical laboratory values, ECG measures and vital signs
Secondary endpoint:
  • Long term efficacy including IGA and EASI responses, PP-NRS4
Inclusion/exclusion criteria2INCLUSION CRITERIA2
  • ≥12 years of age
  • Body weight ≥40 kg if applicable from qualifying parent study
  • Completed the full treatment or full rescue treatment of a qualifying Phase III study, or completed the full open-label run-in of REGIMEN but did not meet response criteria
EXCLUSION CRITERIA2
  • Active forms of other inflammatory skin diseases
  • Presence of other medical or psychiatric conditions that would make the patient inappropriate for entry into the study
  • Pregnant or breastfeeding women
  • Women of childbearing potential who are unwilling to use contraception
  • Discontinued from treatment (or rescue treatment) early in a qualifying Phase III study
  • Ongoing adverse event in qualifying study
POST HOC ANALYSIS – SKIN CLEARANCE & ITCH RELIEFMaintenance of response up to 48 weeks of cumulative treatment with either dose of Cibinqo with or without medicated topical therapy1​​​​​​​

Among patients who achieved response after 12 weeks of treatment and entered JADE EXTEND, the majority of patients maintained their response at Week 48.

Skin clearance and itch relief over 48 weeks1

Included patients who had received Cibinqo in MONO-1, MONO-2, COMPARE and subsequently enrolled in EXTEND, the long-term extension study. If a patient withdrew from the study, then this patient was counted as non-responder after withdrawal.

Data limitations: Not all patients who completed the pivotal studies continued into the long-term extension study. Efficacy improvements seen in this study may be partially due to awareness of receiving active treatment and background medicated topical therapy.

Biases: JADE EXTEND is a parallel treatment assignment study of Cibinqo 200 mg and 100 mg with no placebo control, revealing the certainty of receiving treatment. The lack of placebo control limits the estimate of treatment effect. Due to patients having to complete a qualified parent study and remaining eligible to receive Cibinqo, there may be an enrichment in response based on the patient population. 

​​​​​​​​​​​​​​POST HOC ANALYSIS – SKIN CLEARANCESkin clearance with Cibinqo in patients previously treated with dupilumab1,3​​​​​​​

Patients who received dupilumab in COMPARE and then enrolled in EXTEND were randomised to either Cibinqo 200 mg or 100 mg, once daily.1,3

Proportion of patients achieving EASI-75 and IGA 0/1, 12 weeks post switch to Cibinqo3EASI-75, dupilumab non-responders*​​​​​​​IGA 0/1 dupilumab non-responders†
 
*Dupilumab non-responders are those patients who did not achieve EASI-75 response at Week 16 in JADE COMPARE.
Dupilumab non-responders are those patients who did not achieve IGA 0/1 response at Week 16 in JADE COMPARE.

Data limitations: Not all patients who completed the pivotal studies continued into the long-term extension study. Efficacy improvements seen in this study may be partially due to awareness of receiving active treatment and background medicated topical therapy. Response to Cibinqo 100 mg and 200 mg after previous treatment with dupilumab was assessed as a post-hoc analysis in the subset of patients who received dupilumab in JADE COMPARE and completed the study before entering into JADE EXTEND.

Biases: JADE EXTEND is a parallel treatment assignment study of Cibinqo 200 mg and 100 mg with no placebo control, revealing the certainty of receiving treatment. The lack of placebo control limits the estimate of treatment effect. Due to patients having to complete a qualified parent study and remaining eligible to receive Cibinqo, there may be an enrichment in response based on the patient population.

Explore moreSafety

3,128 patients were treated with Cibinqo in clinical studies in AD representing 2,089 patient-years of exposure.1

View safety guidanceLoading
  • References: 1. Cibinqo (abrocitinib) Summary of Product Characteristics.

Dosing

Learn more about flexible dosing in patients on Cibinqo.

Discover oral once-daily dosingLoading

AD=atopic dermatitis; AE=adverse event; CI=confidence interval; EASI=Eczema Area and Severity Index; IGA=Investigator’s Global Assessment; LTE=long term extension; PP-NRS=Peak Pruritus Numerical Rating Scale.

Prescribing information:
Cibinqo (abrocitinib) Prescribing Information (Great Britain) – 200 mg film-coated tablets.
Cibinqo (abrocitinib) Prescribing Information (Great Britain) – 100 mg film-coated tablets.
Cibinqo (abrocitinib) Prescribing Information (Great Britain) – 50 mg film-coated tablets.

References:

Cibinqo (abrocitinib) Summary of Product Characteristics.ClinicalTrials.gov. NCT03422822. Available from: https://www.clinicaltrials.gov/ct2/show/NCT03422822.Shi V, et al. Abstract presented at SDDS, 2021.
PP-CIB-GBR-0066. October 2021

Cibinqo Risk Minimisation Programme (RMP) materials, including a Patient Card and Prescriber Brochure, are available from https://www.medicines.org.uk/emc. Patients treated with Cibinqo should be given the Patient Card.

JADE EXTEND
Explore the JADE clinical trials
Explore the JADE clinical trials

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search 

for MHRA Yellow Card in Google Play or Apple App Store


Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc


This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ


Copyright © 2021 Pfizer Limited. All rights reserved.


VAT registration number GB201048427

PP-PFE-GBR-3849. November 2021

Add indication message here. It can link a link,
and you can EMBOLDEN text

OK, We will need you to sign in before we can determine if you are aligned with a Pfizer promotional colleague.

If you have already registered with pfizerpro.co.uk and select ‘yes’, you will be directed to the sign-in page where you will be required to enter your username and password.

Would you like to register or sign in now?

You are now leaving PfizerPro
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

​​​​​​​Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
​​​​​​​
For UK Healthcare Professionals *

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-3863. November 2021

Yes No
You are now leaving PfizerPro
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​